



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 24522

Title: Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer

Reviewer's code: 01333314

Reviewer's country: Spain

Science editor: Jing Yu

Date sent for review: 2016-01-27 12:57

Date reviewed: 2016-02-27 14:13

| CLASSIFICATION | LANGUAGE EVALUATION | SCIENTIFIC MISCONDUCT | CONCLUSION |
|---|--|--|--|
| <input type="checkbox"/> Grade A: Excellent | <input checked="" type="checkbox"/> Grade A: Priority publishing | Google Search: | <input type="checkbox"/> Accept |
| <input type="checkbox"/> Grade B: Very good | <input type="checkbox"/> Grade B: Minor language polishing | <input type="checkbox"/> The same title | <input type="checkbox"/> High priority for publication |
| <input checked="" type="checkbox"/> Grade C: Good | | <input type="checkbox"/> Duplicate publication | |
| <input type="checkbox"/> Grade D: Fair | <input type="checkbox"/> Grade C: A great deal of language polishing | <input type="checkbox"/> Plagiarism | <input type="checkbox"/> Rejection |
| <input type="checkbox"/> Grade E: Poor | <input type="checkbox"/> Grade D: Rejected | <input checked="" type="checkbox"/> No | <input checked="" type="checkbox"/> Minor revision |
| | | BPG Search: | <input type="checkbox"/> Major revision |
| | | <input type="checkbox"/> The same title | |
| | | <input type="checkbox"/> Duplicate publication | |
| | | <input type="checkbox"/> Plagiarism | |
| | | <input checked="" type="checkbox"/> No | |

COMMENTS TO AUTHORS

Although the study has been done in a small subset of patents treated with chemotherapy plus bevacizumab in first and second-line therapy and it's exploratory it's interesting because shows that patients with response to therapy are those with a higher decrease of free VEGF (not bound to bevacizumab). I have only minor comments 1. In patients and methods it should be stated when the authors performed radiological evaluation of response 2. Figure 4 does not reflect well changes in free VEGF and total VEGF (it should be modified) 3. there were 4 cases in adjuvant treated with FOLFOX alone (as a control arm). It should be state when the second evaluation was placed in patients and methods.



ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 24522
Title: Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer
Reviewer's code: 02451447
Reviewer's country: United States
Science editor: Jing Yu
Date sent for review: 2016-01-27 12:57
Date reviewed: 2016-02-28 04:52

Table with 4 columns: CLASSIFICATION, LANGUAGE EVALUATION, SCIENTIFIC MISCONDUCT, CONCLUSION. It contains checkboxes for various evaluation criteria like 'Grade A: Excellent', 'Priority publishing', 'Google Search', etc.

COMMENTS TO AUTHORS

The authors showed that the ratio of free VEGF to total VEGF serum and BV plasma concentrations for predicting the response to BV plus oxaliplatin-based chemotherapy could be a promising biomarker of response to BV. The study is well-written and designed. Comments: 1. Histologically confirmed mCRCs were included in this study. The tumor differentiation (low or high grade) may also influence the treatment effect and VEGF concentration. If the authors can categorize the tumor differentiation, this maybe more helpful to choose patients for different treatment regimen. 2. Besides endothelial cells, tumor cell itself can also produce VEGF. Have the authors see difference of tumor size decrease and low VEGF? Angio 2 is mainly produced by endothelial cells, maybe that is the reason there is no change in its concentration. The authors may add these in the discussion.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 24522

Title: Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer

Reviewer's code: 02533652

Reviewer's country: India

Science editor: Jing Yu

Date sent for review: 2016-01-27 12:57

Date reviewed: 2016-03-02 16:29

| CLASSIFICATION | LANGUAGE EVALUATION | SCIENTIFIC MISCONDUCT | CONCLUSION |
|--|---|--|--|
| <input type="checkbox"/> Grade A: Excellent | <input type="checkbox"/> Grade A: Priority publishing | Google Search: | <input type="checkbox"/> Accept |
| <input checked="" type="checkbox"/> Grade B: Very good | <input checked="" type="checkbox"/> Grade B: Minor language polishing | <input type="checkbox"/> The same title | <input type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C: Good | | <input type="checkbox"/> Duplicate publication | |
| <input type="checkbox"/> Grade D: Fair | <input type="checkbox"/> Grade C: A great deal of language polishing | <input type="checkbox"/> Plagiarism | <input type="checkbox"/> Rejection |
| <input type="checkbox"/> Grade E: Poor | | <input checked="" type="checkbox"/> No | <input checked="" type="checkbox"/> Minor revision |
| | <input type="checkbox"/> Grade D: Rejected | BPG Search: | <input type="checkbox"/> Major revision |
| | | <input type="checkbox"/> The same title | |
| | | <input type="checkbox"/> Duplicate publication | |
| | | <input type="checkbox"/> Plagiarism | |
| | | <input checked="" type="checkbox"/> No | |

COMMENTS TO AUTHORS

Dear Authors, Taking into view the clinical importance of your study I find it worthy of publication provided the rebuttal of some of my comments, and also mentioning the limitations of the study clearly. Regards